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Summary
 
CD4 and CD8 are thought to function as coreceptors by binding to the cognate major histo-
compatibility complex (MHC) molecules recognized by the T cell antigen receptor (TCR)
and initiating the signal transduction cascade. We report that during T cell–antigen-presenting
cell interaction, triggered TCRs and coreceptors are downregulated and degraded with identi-
cal kinetics. This coordinated disappearance takes place whenever the TCR is triggered, even
when the coreceptor does not engage the cognate MHC molecule and is the consequence of
binding of the coreceptor-associated Lck to ZAP-70. The interaction of coreceptor and cog-
nate MHC molecules is dispensable when T cells are stimulated by optimal ligands, but be-
comes crucial when suboptimal ligands are used. In the latter case the coreceptor increases the
efficiency of TCR triggering without changing the activation threshold or the quality of the T
cell response.
 
B
 
ecause of their capacity to bind to the same MHC
molecule as that engaged by the TCR (1, 2), and be-
cause of their association with the tyrosine kinase Lck (3),
CD4 and CD8 have been defined as coreceptors (4, 5). The
binding of coreceptor to the cognate MHC molecule is
thought to perform two functions: (
 
a
 
) to stabilize the TCR–
peptide MHC interaction (6–8); and (
 
b
 
) to carry Lck in con-
tact with the TCR to initiate phosphorylation events (9).
Indeed, cross-linking of TCRs and coreceptors results in
enhanced T cell response (10, 11), whereas interference with
the coreceptor–MHC interaction inhibits T cell activation
or changes the quality of the response (12–14).
However, there are clear cases where the interaction of
coreceptors with cognate MHC molecules appears to be
dispensable for full T cell activation (15). These findings raise
the question of whether the contribution of the coreceptor
to T cell activation is qualitative, in the sense that it pro-
vides signals additional to and different from those provided
by TCR alone, or whether the coreceptor acts by facilitat-
ing the triggering of TCRs when the interaction has lower
than optimal kinetics.
We report that during T cell–APC interaction, the core-
ceptors are recruited to triggered TCRs and are downregu-
lated with identical kinetics, even when the coreceptor
does not engage the cognate MHC molecule. This process
is the consequence of the binding of coreceptor-associated
Lck to ZAP-70/
 
z
 
 and takes place whenever the TCR is
triggered. We also show that the contribution of the core-
ceptors becomes crucial when suboptimal ligands are used.
 
In this case, engagement of the coreceptor with the cog-
nate MHC molecule increases the efficiency of serial TCR
triggering without changing the activation threshold or the
quality of the T cell response.
 
Materials and Methods
 
T Cell Clones.
 
HLA-DR1101–restricted (KS140, KS70, and
KS164) and DR1302-restricted (AL15.1) CD4
 
1
 
 T cell clones
specific for tetanus toxin (TT)830-843 peptide and HLA-A2–
restricted CD8
 
1
 
clones (CER22, CER43) specific for the influenza
matrix (M) 58–66 peptide were used. T cell clones were conju-
gated with EBV-transformed B (EBV-B) cells pulsed with various
concentrations of either peptide or bacterial superantigens (toxic
shock syndrome toxin or staphylococcal enterotoxin B) or monova-
lent  anti-CD3 antibodies (W632/T3 or L243/T3) as described
(16). CD4
 
1
 
CD8
 
1
 
 alloreactive T cell clones were isolated by sorting
double positive cells from a primary MLR. CD8
 
1
 
 alloreactive T
cell clones that recognize class II molecules on the class I
 
2
 
 EBV-B
.221 cells were generated, stimulating PBMC with irradiated .221
cells, followed by sorting and cloning of the CD8
 
1
 
CD4
 
2
 
 cells.
The class II specificity of the clones was verified using a panel of
typed EBV-B cells as well as inhibition by anti–class II antibodies.
 
FACS
 
Ò
 
 
 
Analysis.
 
T cells were conjugated with autologous
EBV-B cells pulsed with peptide, superantigen, or anti-CD3 for 5 h
at 37
 
8
 
C. Downregulation and degradation of TCR/CD3 and
coreceptors were measured by indirect immunofluorescence on
intact and permeabilized cells as previously described (17, 18) us-
ing antibodies to CD3 (OKT3 or Leu3a), CD4 (6D10), and CD8
(OKT8). The absolute numbers of CD3, CD4, and CD8 mole-
cules per cell were estimated by reference to a standard curve of
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beads coated with known amounts of mouse Ig (Flow Cytometry
Standards Europe, Leiden, The Netherlands).
 
Immunoprecipitations and Kinase Assays.
 
T cells were stimu-
lated or not with the appropriate APC for 2 min at 37
 
8
 
C and ly-
sed for 30 min at 4
 
8
 
C in 1% Brij96 buffer (20 mM Tris-HCl, pH
7.5, 150 mM NaCl, 1 mM MgCl
 
2
 
, and 1 mM EGTA) in the
presence of protease and phosphatase inhibitors (10 
 
m
 
g/ml aproti-
nin, 10 
 
m
 
g/ml leupeptin, 1 mM Pefabloc-SC, 50 mM NaF, 10 mM
Na
 
4
 
P
 
2
 
O
 
7
 
, and 1 mM NaVO
 
4
 
). CD4 immunoprecipitation, in
vitro kinase assay, and reimmunoprecipitation with anti–ZAP-70
or anti-
 
z
 
 were performed as previously described (19, 20) using
the following antibodies: 19Thy-5D7 (IgG2a, anti-CD4), 21Thy-
2D3 (IgG1, anti-CD8), and rabbit polyclonal antibodies to ZAP-
70 and 
 
z
 
.
 
Drugs and Transfection.
 
Genistein and herbimycin A were
purchased from Calbiochem (La Jolla, CA) and used as previously
described (21). After overnight treatment with herbimycin, which is
required to deplete Lck, the expression of coreceptor was reduced
by 
 
z
 
50%. cDNAs encoding wild-type human CD4 and the mu-
tant CD4.401 molecule that does not associate with Lck were a
gift of Dr. Dan Littman (Skirball Institute of Biomolecular Medi-
cine, NYU Medical Center, New York; reference 22). The cDNA
was subcloned in the pSAM-EN retroviral vector (23) using the
SalI–XhoI restriction sites. Plasmid DNA was purified and trans-
fected in the amphotropic packaging cell line PA317 as previously
described (22). The transduction of Jurkat cells was done as previ-
ously described (22).
 
Substituted Peptides and Anticoreceptor Antibodies.
 
Several sub-
stituted analogs of TT830-843 were tested for their capacity to
trigger T cell proliferation, and peptides with unaltered capacity
to bind to DR molecules but weaker T cell stimulatory capacity
were selected. Blocking anti-CD4 antibodies (M-T310, M-T413,
M-T414, and M-T435) and anti-CD8 (733) were a gift of Dr.
E.P. Rieber (Institute of Immunology, Technical University Dres-
den, Germany) and Dr. E. Roosnek (University Hospital, Geneva,
Switzerland). Antibodies were used in the culture at 10 
 
m
 
g/ml.
 
Results
 
Parallel Downregulation and Degradation of the Coreceptor
and TCR.
 
To understand the contribution of the core-
ceptor to TCR triggering and T cell activation, we studied
the TCR–coreceptor interaction in T cells stimulated by a
specific ligand. It has been shown that, after triggering by
agonists, TCRs are downregulated and degraded and this
downregulation can be used to measure the number of
TCRs triggered (17, 18). Therefore, we investigated whether
the CD4 or CD8 coreceptors would also be downregulated
together with the TCR. We observed that in specific T–APC
conjugates, TCRs and coreceptors are downregulated with
the same kinetics and with fixed stoichiometry (Fig. 1, 
 
A
 
 and
 
B
 
). In addition, downregulation is followed by rapid degra-
dation of both coreceptor and TCR (Fig. 1 
 
C
 
). By refer-
ence to a standard curve of Ig-coated beads, we estimated
that approximately two CD4 or four CD8 molecules are
downregulated for each TCR (data not shown), an esti-
mate which is consistent with that reported for CD4 by
Saizawa and Janeway (24).
 
Intracellular Recruitment of Coreceptor to Triggered TCRs in
the Absence of an Interaction with Cognate or Noncognate MHC
Molecules.
 
We investigated whether the codownregula-
tion of TCR and coreceptor would require the interaction
between coreceptor and cognate MHC molecule or whether
it would simply be a consequence of TCR triggering.
Three lines of evidence indicate that coreceptor downreg-
ulation can occur in the absence of interaction with the
cognate MHC molecule. First, a parallel downregulation of
TCR and coreceptor was induced not only by specific
peptide–MHC complexes, but also by bacterial superanti-
Figure 1. Parallel downregulation
and degradation of CD4 and CD8 to-
gether with CD3 in T cell clones stimu-
lated by specific antigen. (A) Time
course of CD3 (d) and CD4 (n) down-
regulation in clone KS140 stimulated
with APCs pulsed with 10 nM TT830-
842. (B) CD3 (d) and CD8 (h) down-
regulation in clone CER22 stimulated
with APCs pulsed with 100 nM M58-
66. (C) Surface and total levels of CD3 and CD4 as determined by staining before and after permeabilization in KS70 cells conjugated for 5 h with APCs
unpulsed (empty bars) or pulsed with 0.1 mM (hatched bars) or 10 mM (filled bars) TT830-842.
Figure 2. Downregulation of coreceptors can occur in the absence of
an interaction with cognate or noncognate MHC molecules. Downregu-
lation of CD3 and coreceptor in CD41 (KS70; A) or CD81 (CER43; B)
T cell clones stimulated by specific peptide–MHC (d), superantigens
(h), or monovalent anti-CD3 antibodies: w632/T3 (n), L243/T3 (s).
(C) Downregulation of CD3 versus CD4 (m) and CD8 (s) in alloreac-
tive CD41 CD81 T cell clones stimulated by specific alloantigen (D).
Downregulation of CD3 and CD8 in CD81, class II–alloreactive T cell
clones stimulated with class I2 APCs (.221) expressing the relevant class II
alloantigen. 
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gens or monovalent anti-CD3 antibodies (Fig. 2, 
 
A
 
 and 
 
B
 
).
Second, class I–restricted T cell clones expressing both CD4
and CD8 downregulated both coreceptors to the same ex-
tent (Fig. 2 
 
C
 
). Third, class II–alloreactive CD8
 
1
 
 T cell
clones, when stimulated by class II
 
1
 
 APCs lacking class I
molecules, downregulated CD8 together with TCR (Fig.
2 
 
D
 
).
The mechanism responsible for the downregulation of
the coreceptor was next investigated. Three lines of evi-
dence indicate that the downregulation of the coreceptor
was due to an intracellular association with triggered TCRs.
First, immunoprecipitation experiments showed that, as
previously demonstrated in Jurkat cells activated by anti-
CD3 antibodies (19, 20), a complex-containing coreceptor,
Lck and ZAP-70, is formed after T cell activation by a spe-
cific ligand (Fig. 3 
 
A
 
). Comparable results were obtained
when the reimmunoprecipitation was performed with ei-
ther anti–ZAP-70 or anti-
 
z
 
. Second, treatment with the
Lck inhibitors genistein or herbimycin A does not interfere
with TCR downregulation, but completely inhibits core-
ceptor downregulation (data not shown). Third, truncated
CD4 molecules that fail to associate with Lck are not
downregulated with triggered TCRs (Fig. 3 
 
B
 
).
 
Quantitative Contribution of Coreceptor to TCR Triggering
and T Cell Activation.
 
Taken together, the above results
demonstrate that coreceptors become associated to, and are
downregulated together with, triggered TCRs, and that
this process can occur after TCR triggering, even in the
absence of interaction of the coreceptor with the cognate
MHC molecules. However, these results do not explain how
coreceptors contribute to T cell antigen recognition in
most cases. Considering the serial engagement model (25),
it is conceivable that the requirement for coreceptor might
vary with the kinetics of the TCR–ligand interaction. Al-
though ligands with optimal kinetics might efficiently trig-
ger TCRs even in the absence of coreceptor, ligands with
higher off-rates may require the extracellular interaction of
the coreceptor with the cognate molecule to increase the
stability of the complex and, consequently, the rate of trig-
gering.
To address this point, we stimulated T cell clones with
ligands of different potency and tested the effect of CD4 or
CD8 antibodies on the extent of TCR triggering, the T cell
activation threshold, and the quality of the response. As
shown in Fig. 4, the proliferative response of T cell clone
KS70 was not affected by anti-CD4 antibody when the clone
was triggered by the bacterial superantigen TSST, but
was inhibited by anti-CD4 when the clone was triggered
by peptide–MHC complexes. Interestingly, clone KS164,
which displayed a better dose–response curve to the same
peptide–DR complex, was not inhibited by anti-CD4. How-
ever, this clone became sensitive to inhibition when a modi-
fied peptide with weaker agonistic properties was used. Com-
parable results were obtained with two additional CD4
 
1
 
and two additional CD8
 
1
 
 clones, indicating that the sensi-
tivity to inhibition by anticoreceptor antibodies is inversely
correlated to the efficiency of the TCR–ligand interaction.
To investigate whether the lower response of T cells in
the presence of anti-CD4 antibodies reflects a lower extent
of TCR triggering or, rather, an altered signal leading to
Figure 3. Intracellular associa-
tion of coreceptor with triggered
TCRs. (A) T cell clones were
stimulated (1) or not (2) with
APCs, lysed, and the CD4 or
CD8 immunoprecipitates were
subjected to an in vitro kinase as-
say, followed by reimmunopre-
cipitation with anti–ZAP-70 an-
tiserum. CD41 clone KS140
conjugated with peptide-pulsed
or unpulsed APCs (lanes 1 and
2). CD81 clone MS3 either un-
treated or conjugated with allogeneic class I2 APC (lanes 3 and 4). (B)
Downregulation of CD3 (s, d) and CD4 (n, m) in CD42 Jurkat cells
transfected with wild-type CD4 (n, s) or with mutant CD4.401 (m, d).
Figure 4. The sensitivity to
inhibition by anti-CD4 depends
on the nature of the ligand. (A
and B) Proliferative response of
clone KS70 to various doses of
TSST or TT830-843 in the
presence (m) or absence (n) of
anti-CD4. (C) Proliferative re-
sponse of clone KS164 to
TT830-843 (d, s) or to
TT830-843 Ala839-substituted
peptide that behaves as a weak
agonist (j, h) in the presence
(d, j) or absence (s, h) of
anti-CD4.1778 Quantitative Contribution of CD4 and CD8 to TCR Serial Triggering
qualitatively different responses, we correlated TCR down-
regulation and cytokine production in T cells stimulated by
strong or weak agonists in the presence or absence of anti-
CD4 antibodies. As shown in Fig. 5, the inhibition of T
cell response by anti-CD4 antibodies precisely correlated
with a reduced level of TCR downregulation both when
strong and weak agonists were used. These results indicate
that the anti-CD4 antibody mimics the effect of a weak ag-
onist, i.e., results in a decreased efficiency of serial trigger-
ing. However, in spite of a decreased efficiency of TCR
triggering, the threshold of T cell activation and the type of
cytokines produced were not affected by anti-CD4. In-
deed, T cells produced IFN-g, IL-2, and TNF-a when
z20–30% of TCRs were triggered, irrespective of the
strength of the agonist and of the presence or absence of
anti-CD4. IL-3 production consistently required higher
levels of TCR occupancy, which were comparable in all
experimental conditions.
Discussion
Our results reconcile several apparently contradictory
observations concerning coreceptor dependency and the role
of extracellular and intracellular interactions in coreceptor
function. We have shown that in T cells activated by pep-
tide–MHC, superantigens, or anti-CD3 antibodies the co-
receptors are recruited to triggered TCRs and are down-
regulated and degraded together with them. This process
does not necessarily require the interaction of the corecep-
tor with the cognate MHC molecule, but takes place
whenever the TCR is triggered via the intracellular associ-
ation of Lck and ZAP-70/z.
It is interesting that even in unstimulated T cell clones z
and ZAP-70 can be immunoprecipitated by anti-CD4 or
anti-CD8 antibodies, although the complexes contain only
low levels of kinase activity. This finding suggests that in
human as well as mouse T cells a fraction of TCRs is con-
stitutively associated with the coreceptor (26). This associa-
tion may be responsible for the constitutive association of
phospho-z and ZAP-70 observed in thymocytes and lymph
node T cells (27). It is tempting to speculate that the con-
stitutive association of TCR and coreceptors might play a
role in inducing positive selection by self-ligands in the
thymus as well as in facilitating the response to low-affinity
ligands in periphery.
There is clear evidence that coreceptor can stabilize the
TCR/peptide–MHC interaction (6–8). We have shown here
that this stabilization may actually result in an increased rate
of TCR triggering. Indeed, the coreceptor appears to be
dispensable when the ligands have optimal kinetics, allow-
ing efficient serial TCR triggering. However, the binding
of coreceptor to cognate MHC molecules becomes critical
in the case of low-affinity ligands because in this case the
coreceptor can initially stabilize the TCR–ligand interac-
tion, thus increasing the probability that an engagement
event will result in triggering.
Our results also show that coreceptors play a quantitative
role in T cell activation. Indeed the reduced response ob-
served in cultures stimulated with suboptimal ligands or in
the presence of anticoreceptor antibodies can be fully ac-
counted for by a reduced level of TCR triggering. The fact
that the T cell activation thresholds and the profile of cy-
tokines produced are comparable in all conditions of stimu-
lation is not surprising. Indeed, in all cases the triggered
TCRs have been shown to be complexed with corecep-
tors, suggesting similar composition and transduction ca-
pacity of the signaling complexes.
Figure 5. Quantitative contri-
bution of CD4 to TCR trigger-
ing and T cell activation. (A)
IFN-g production by T cell
clone AL15.1 stimulated by
TT830-843 (d, s) or by
TT830-843 Gln839 (m, n) in the
presence (d,m) or absence (s,
n) of anti-CD4 antibody. (B)
CD3 downregulation in the
same experiment. (C–E) Levels
of IFN-g (m), IL-2 (d), TNF-a
(j), and IL-3 (n) as a function
of the number of TCRs down-
regulated in cultures stimulated
by wild-type agonist (C), wild-
type agonist 1 anti-CD4 (D), or
weak agonist (E). No cytokine
production was observed in cul-
tures stimulated by weak agonist
1 anti-CD4.1779 Viola et al. Brief Definitive Report
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